<DOC>
	<DOCNO>NCT00458367</DOCNO>
	<brief_summary>The purpose research study gather information safety efficacy risperidone use routine clinical practice .</brief_summary>
	<brief_title>RiSPECT : Risperdal Safety Protocol Evaluation Consta Treatment , Post Authorization Safety Survey Obtain Information Safety Efficacy Risperidone When Used Routine Clinical Practice</brief_title>
	<detailed_description>This post-authorisation safety survey ( PASS ) international , multicentre , naturalistic , descriptive survey confirm safety risperidone daily practice . This single-arm , prospective , observational survey compare safety profile group define exist risk disease factor patient characteristic . The study duration 6 month 4 patient visit . The primary objective PASS confirm safety , identified phase III clinical trial risperidone , collect data drug use market condition routine clinical practice . A secondary objective evaluate effectiveness reason initiate risperidone . Each investigator document data 4-10 treat patient risperidone long-acting injectable ( RLAI ) treatment determine clinically indicate . Risperidone long-acting injectable ( RLAI ) give intramuscular injection every 2 week . The start dose RLAI accordance product label ( usually 25 mg ) . If necessary , dosage injection may increase gradually . Treatment duration 26 week . To ensure continue antipsychotic coverage main release risperidone microspheres , previous antipsychotic therapy continue concomitantly first three week study .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>All patient treat longacting injectable risperidone decide agreement physician patient , accordance local Summary Product Characteristics ( SmPC ) , eligible inclusion survey . According global SmPC , longacting injectable risperidone indicate treatment schizophrenia schizoaffective disorder According SmPC , longacting injectable risperidone contraindicate patient know hypersensitivity product component . These patient must exclude survey</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>PASS</keyword>
	<keyword>Safety Assessment</keyword>
	<keyword>Efficacy Assessment</keyword>
	<keyword>long-acting injectable risperidone</keyword>
</DOC>